Sansure Biotech’s HPV DNA Diagnostic Kit (HPV 13+2) approved by the NMPA
Sansure Biotech’s HPV DNA Diagnostic Kit (HPV 13+2) was approved by the China NMPA on January 6, with reference to the medical device approval released on the NMPA’s official website. This is another blockbuster product from Sansure Biotech in promoting the global elimination of cervical cancer.
In 2020, WHO launched a global strategy to accelerate the elimination of cervical cancer, and proposed to achieve the following targets by 2030: more than 90% of girls fully vaccinated with the HPV vaccine by the age of 15; more than 70% of women screened at least once with a high-performance test by the age of 35, and by the age of 45; and more than 90% of women identified with CIN or cervical cancer are accessible to treatment and management. It is reported that the current coverage of cervical cancer screening in China is less than 40%, suggesting a large gap from the vision of eliminating cervical cancer. In response to the challenging prevention and control of cervical cancer, the urgent need to improve coverage, and the WHO’s vision of eliminating cervical cancer, Sansure Biotech has launched the HPV DNA Diagnostic Kit (HPV 13+2).
Over the 8 years, Sansure Biotech has been deeply engaged in women’s and children’s health as the focus of Sansure Biotech’s “Quality Engineering”. A complete range of product portfolios are created to provide comprehensive and accessible integrated solutions for the early screening, diagnosis and treatment of HPV infection and cervical cancer, covering application scenarios including outpatient, physical examination, fast testing and livelihood screening. The product is used in major hospitals and laboratories in China to serve cervical cancer/breast cancer screening in many provinces and cities; it is also exported to more than 20 countries worldwide, including France, Spain, Thailand, etc., making great contributions to the WHO’s vision of global elimination of cervical cancer.